Resistance is nowadays the rule rather than the exception for the four currently available antifungal classes, making it difficult - if not impossible – to treat many invasive fungal infections.

Brexafemme is the first antifungal in what is only the fourth antifungal class to reach the market, and has data showing activity in three of four MDR infections on the World Health Organization ...

F2G is a biotech company that specializes in developing therapies to treat invasive fungal infections through a novel class of antifungal agents called the orotomides. There are at least 5 million ...

PORTLAND, KS, UNITED STATES, February 6, 2025 /EINPresswire / -- Rise in incidences of fungal and nosocomial infections, surge in initiatives by public and private organizations to spread awareness ...

Provide cost-efficient care through optimal resource utilization and appropriate antifungal drug choice. Reduce indiscriminate use of fungicides and establish evidence-based treatment guidelines.

auris's FKS1 gene cause resistance to echinocandins, which are the class of antifungal drugs that currently serve as the first line treatment for invasive C. auris infections. Specifically ...